Dr. Reddy's Laboratories LimitedNYSE
Advanced Chart
  • Mon, Jun. 13, 3:14 AM
    • Looking to bolster its U.S. business, Dr. Reddy's Laboratories (NYSE:RDY) has agreed to buy eight generic medicines from Teva Pharmaceutical (NYSE:TEVA) and Allergan (NYSE:AGN) for $350M in cash.
    • The sale to India's second-largest drugmaker could put Teva a step closer to winning U.S. antitrust clearance for its $40.5B acquisition of Allergan's generic drugs portfolio, and is contingent on the deal's approval.
    | Mon, Jun. 13, 3:14 AM | 1 Comment
  • Apr. 6, 2015, 7:43 AM
    • Dr. Reddy's Laboratories (NYSE:RDY) acquires a portfolio of established products from Belgian firm UCB for INR 800 Crores (€118M) for the territories of India, Nepal, Sri Lanka and Maldives. The transaction includes ~350 employees currently working in India. The dermatology, respiratory and pediatrics products generated ~INR 150 Crores (€22M) in revenues in 2014. They include the brands Atarax, Nootropil, Zyrtec, Xyzal and Xyzal M.
    • The deal is expected to close in FQ1 (calender Q2 2015).
    • Brussels-based UCB generated revenues of €3.3B last year.
    | Apr. 6, 2015, 7:43 AM
  • Apr. 1, 2015, 6:58 AM
    • Dr. Reddy's Laboratories (NYSE:RDY) acquires certain established drug brands from Belgian firm UCB SA in India, Sri Lanka and the Maldives for 8B rupees (~$128M). The transaction will boost Reddy's presence in dermatology, pediatrics and respiratory. The products generated top line sales of 1.5B rupees (~$24M) last year.
    | Apr. 1, 2015, 6:58 AM
  • Nov. 26, 2014, 3:48 PM
    • The Federal Trade Commission approves GlaxoSmithKline's (GSK +0.4%) proposed acquisition of Novartis' (NVS +0.6%) vaccines business and the proposed creation of a consumer healthcare joint venture between the two firms.
    • As a condition of the positive vote, Novartis will divest its private label nicotine replacement therapy transdermal patch, Habitrol, in the U.S. to Dr. Reddy's Laboratories SA (RDY +1.5%).
    | Nov. 26, 2014, 3:48 PM